Navigation Links
UCSF study will test new vaginal microbicide for herpes and HIV

A team of researchers at UCSF is seeking young women to participate in the first U.S. study of the safety of a new a vaginal gel designed to prevent herpes and HIV infection.

If it is effective and approved by the U.S. Food and Drug Administration, the gel would be an important weapon in the fight against HIV because it would allow women to protect themselves from infection rather than relying on their partners to use condoms.

"The significance of the gel is that it potentially gives the power back to the woman to protect herself against infection," said Anna-Barbara Moscicki, MD, professor of pediatrics at UCSF and lead investigator for the study.

The gel is not a contraceptive, but a microbicide. Microbicidal gels or creams are inserted into the vagina solely to prevent the spread of HIV and other sexually transmitted diseases. There are currently no such products on the market. Women who have herpes are at increased risk of contracting HIV, so diminishing the risk of getting herpes also diminishes the risk of HIV infection.

The generic name of the gel is "3 % w/w SPL7013" (brand name VivaGel). Following this safety trial, other trials will be conducted to determine its effectiveness at fighting off herpes and HIV infection. But Moscicki said that trials in animals have found the gel to be nearly 100 percent effective and have few side effects.

"There has been an important move supported by the National Institutes of Health and World Health Organization to support the development of vaginal microbicides," said Moscicki, who also is the director of Teen Clinics in the Division of Adolescent Medicine at UCSF Children’s Hospital. "Herpes infection is the number one attributable cause of HIV infection in the United States and worldwide."

The gel is designed to prevent herpes and HIV infection through the use of a molecule called a dendrimer. Dendrimers have molecular structures that resemble the branches of a
'"/>

Source:University of California - San Francisco


Page: 1 2 3

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis

Post Your Comments:
(Date:12/3/2009)... BIO-key International, I...ss public safety and finger-based biometric identi...ts shareholders at a Special Shareholder Meeting h...nforcement Division to Interact911 Mobile Systems ... and 1.2% were opposed. ,, (Logo: http://www.n...
(Date:12/3/2009)... and his co-workers discovered that specific types...er. Scientists soon found out how these pathogens ...the main culprits are viral proteins E6 and E7. Bo...functions, thus promoting cell growth. , Profes...now discovered another mechanism by which the E6 o...
(Date:12/3/2009)...rmation and adapt to changes in our daily environm...rs to lie in the minute junctions where nerve cell...gone Medicine Center researchers. The study is pub..., The scientists, led by Wen-Biao Gan, PhD, asso...NYU School of Medicine, discovered that a delicate...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Papillomavirus silences innate immune response 2Lifelong memories linked to stable nerve connections 2Chindex International Inc Launches World Class Cancer Treatment Center 53897 1Chindex International Inc Launches World Class Cancer Treatment Center 53897 2Chindex International Inc Launches World Class Cancer Treatment Center 53897 3Chindex International Inc Launches World Class Cancer Treatment Center 53897 4AMN Healthcare Announces Second Quarter 2009 Results 53895 1AMN Healthcare Announces Second Quarter 2009 Results 53895 2AMN Healthcare Announces Second Quarter 2009 Results 53895 3AMN Healthcare Announces Second Quarter 2009 Results 53895 4AMN Healthcare Announces Second Quarter 2009 Results 53895 5AMN Healthcare Announces Second Quarter 2009 Results 53895 6AMN Healthcare Announces Second Quarter 2009 Results 53895 7AMN Healthcare Announces Second Quarter 2009 Results 53895 8AMN Healthcare Announces Second Quarter 2009 Results 53895 9AMN Healthcare Announces Second Quarter 2009 Results 53895 10AMN Healthcare Announces Second Quarter 2009 Results 53895 11AMN Healthcare Announces Second Quarter 2009 Results 53895 12AMN Healthcare Announces Second Quarter 2009 Results 53895 13AMN Healthcare Announces Second Quarter 2009 Results 53895 14AMN Healthcare Announces Second Quarter 2009 Results 53895 15AMN Healthcare Announces Second Quarter 2009 Results 53895 16Osteotech to Present at the Canaccord Adams 29th Annual Global Growth Conference 53893 1
...30 BIO-key International, Inc. (OTC Bulletin Boar...arter 2009 financial results on Wednesday, May 6, ... the release, BIO-key has scheduled a conference c...t on Wednesday, May 6, 2009 at 10:00 a.m. Eastern ...n/prnh/20050509/BIOKEYLOGO ) , , , What: BI...
...sts from Canada, Spain and the United States has i...themselves against environmental stresses like dro...ormones that they produce naturally and that signa...am member Peter McCourt, a professor of cell and s...we can control these hormones we should be able to...
...Ind. - Fish don,t make noises or contort their fac...m their mouths, but a Purdue University researcher...eph Garner, an assistant professor of animal scien...feel pain, and their reactions to it are much like... published in the early online version of the jour...
Other Biology News:BIO-key(R) Announces First Quarter Earnings Release and Conference Call Schedule 2International team finds key gene that allows plants to survive drought 2Fish may actually feel pain and react to it much like humans 2
(Date:12/3/2009)..., , HOUSTON, Dec. 3 ...it has updated its facility to offer patients a se... , along with the LAP-BAND® System that it ...rocedure at the facility was performed by surgeon ...2009. The patient is reported as doing well. ,,...
(Date:12/3/2009)..., , MELVILLE, N.Y., Dec. 3 /PRNewswire/ -...cal instruments, announced today that it has signe...anting Nikon the rights to use the Stochastic Opti...Under the terms of the agreement, Nikon will manuf... them with the N-STORM name. ,, Nikon Corporat...
(Date:12/3/2009)..., , DALLAS, Dec. 3 /PRNewswire-First...ulletin Board: ACCP), today provided an update on ...pproved treatment for oral mucositis, a debilitati...rapy. MuGard is commercially launched by Access, p...ding the UK, Germany, Italy, Norway, Greece and Sw...
(Date:12/3/2009)..., , SAN FRANCISCO, Dec. 3 /PRNewswire-Fir...P ), a biotechnology company focused on the develo...ular and metabolic disease, today announced that i...e 2 FDG-PET clinical trial of VIA-2291. ,, The...d out at five sites in the US and Canada including...
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
... from the National Institute of Standards and Tech...have learned how to tweak a new class of polymer-b... and alignment of the components of the blend. The...could enable the design of practical, large-scale ...able, flexible electronic displays and other devic...
... us, gold is only valuable if we possess it in lar...ule isn,t the case for those interested in exploit...variety of chemical reactions, including the oxida...ss carbon dioxide at room temperatures. That proce...he effectiveness of catalytic converters that clea...
..., Sept. 5 Pharmasset, Inc.,(Nasdaq: VRUS ) manag...Day,being held September 8, 2008, at the Citi Exec...will also present at the Morgan Stanley Global,Hea... at the Grand Hyatt,Hotel, New York, NY. Schaefer ...rovide a brief overview of the company followed by...
Other Biology Technology:Bottoms up: Better organic semiconductors for printable electronics 2NIST and partners identify tiny gold clusters as top-notch catalysts 2Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences 2
... Detection Kit contains a green fluorescent-labele...scein (FAM) derivative of valylalanylaspartic acid...or of caspase activity. When added to a populatio...h cell and covalently binds to a reactive cysteine...
Complement, Guinea Pig Serum from Calbiochem
...em, 220-240 V, uses floating pin printing technolo...hydrates, lipids, and other biomolecules onto a va...his system can generate high-density arrays with g...r than 57,000 spots per membrane with a capacity o...
...are high-precision microarrayers capable of printi...sArray ChipWriter Pro systems set new standards fo... deliver unparalleled quality arrays on a variety ...flexible software easily adapt to either micro-run...
Biology Products: